A Phase 2 interventional study of mRNA-1010 and mRNA-1010.4 in Influenza, sponsored by ModernaTX, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-20.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.
Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 9th largest by enrollment, is one of 2 that started in 2023, is one of 2 in phase 2, and was the 9th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 4 · Phase 4 1
First in 2021; this study’s year is marked. 2 started in 2023.
This study's enrollment of 270 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 471 across the 12 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
23 studies in Influenza, Human by Moderna, Inc.: 2 open now, 3 under way, 1 of them phase 3. Of 20 finished, 12 (60%) have results posted.
Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 18th largest by enrollment, is one of 6 that started in 2023, is one of 4 in phase 2, and was the 14th registered.
Moderna, Inc.’s Influenza, Human studies by the year they started, since 2015.
1 of the studies testing mRNA-1010 influenza vaccine in Influenza, Human that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07884175ModernaTX, Inc.A Study of Updated mRNA Seasonal Influenza Vaccines | 2026-12-07 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, from their registry updates:
Among Moderna, Inc.’s 23 in Influenza, Human:
This tab as a report to print or save as PDF → With an account.
The main purpose of the study is to evaluate the safety, reactogenicity, and the immunogenicity of mRNA-1010 vaccine candidate variations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
Biological: mRNA-1010
Participants will receive a single dose of mRNA-1010.4 by IM injection on Day 1.
Biological: mRNA-1010.4
Participants will receive a single dose of mRNA-1010.4 by IM injection on Day 1.
Biological: mRNA-1010.4
Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.
Biological: mRNA-1010.6
Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.
Biological: mRNA-1010.6
Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.
Biological: mRNA-1010.6
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: 7 days post-vaccination
Number of Participants With Unsolicited Adverse Events (AEs)
An unsolicited AE was an AE that was not solicited using a participant diary and that was communicated by a participant who has signed the informed consent. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure.
Time frame: Up to 28 days post-vaccination
Number of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Study or Treatment Discontinuation
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or coronavirus disease 2019 \[COVID-19\] and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (Day 181) are reported in this outcome measure.
Time frame: Day 1 to Day 181 (end of study [EOS])
Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-matched Influenza A and B Strains
Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation.
Time frame: Days 1 (Baseline), 8, 29, 91, and 181
Geometric Mean Fold Rise (GMFR) of Anti-HA Antibodies, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% confidence interval (CI) for GMFR was calculated based on the t distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
Time frame: Baseline, Days 8, 29, 91, and 181
Percentage of Participants With Seroresponse for mRNA-1010, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains
Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroresponse was defined as (a) a post-vaccination antibody titer ≥ 4 \* lower limit of quantification (LLOQ) if baseline (Day 1) antibody titer was \< LLOQ or (b) a post-vaccination antibody titer ≥ 4-fold of baseline antibody titer if baseline antibody titer was ≥ LLOQ.
Time frame: Days 8, 29, 91, and 181
| Milestone | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose |
|---|---|---|---|---|---|---|
| Started | 60 | 30 | 60 | 30 | 30 | 60 |
| Received injection | 60 | 30 | 60 | 30 | 30 | 60 |
| Safety set | 60 | 30 | 60 | 30 | 31 | 59 |
| Solicited safety set | 60 | 30 | 60 | 30 | 31 | 59 |
| Per-protocol set | 55 | 28 | 56 | 29 | 28 | 52 |
| Completed | 54 | 30 | 54 | 26 | 27 | 54 |
| Not completed | 6 | 0 | 6 | 4 | 3 | 6 |
| Withdrew: Lost to follow-up | 5 | 0 | 6 | 4 | 2 | 6 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 1 | 0 |
Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose |
|---|---|---|---|---|---|---|
| Any | 50 | 27 | 53 | 18 | 25 | 55 |
| Grade 1 | 22 | 11 | 11 | 11 | 12 | 15 |
| Grade 2 | 24 | 11 | 32 | 5 | 12 | 34 |
| Grade 3 | 4 | 5 | 10 | 2 | 1 | 6 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
An unsolicited AE was an AE that was not solicited using a participant diary and that was communicated by a participant who has signed the informed consent. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure.
| Participants | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose |
|---|---|---|---|---|---|---|
| Number of Participants With Unsolicited Adverse Events (AEs) | 11 | 4 | 9 | 0 | 4 | 7 |
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or coronavirus disease 2019 \[COVID-19\] and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (Day 181) are reported in this outcome measure.
| Participants | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose |
|---|---|---|---|---|---|---|
| SAEs | 1 | 0 | 2 | 1 | 0 | 1 |
| AESIs | 0 | 0 | 0 | 0 | 0 | 0 |
| MAAEs | 14 | 5 | 12 | 2 | 3 | 8 |
| AEs Leading to Study or Treatment Discontinuation | 0 | 0 | 0 | 0 | 0 | 0 |
Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation.
| titer | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose |
|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody: Day 1 | 52.4 (41.5 to 66.2) | 60.9 (41.9 to 88.7) | 72.9 (53.9 to 98.5) | 78.2 (54.5 to 112.1) | 50.5 (34.2 to 74.6) | 48.2 (36.7 to 63.3) |
| Influenza A H1N1 Antibody: Day 8 | 226.2 (164.8 to 310.6) | 272.4 (196.2 to 378.3) | 337.2 (244.9 to 464.3) | 240.2 (163.8 to 352.2) | 259.3 (166.9 to 403.0) | 331.3 (247.0 to 444.5) |
| Influenza A H1N1 Antibody: Day 29 | 334.4 (247.8 to 451.2) | 316.1 (214.5 to 465.8) | 394.9 (299.1 to 521.5) | 255.0 (177.7 to 366.1) | 269.1 (184.5 to 392.5) | 349.0 (266.9 to 456.3) |
| Influenza A H1N1 Antibody: Day 91 | 168.9 (125.2 to 227.8) | 202.4 (144.2 to 284.2) | 229.3 (174.4 to 301.4) | 160.0 (108.8 to 235.4) | 174.5 (117.0 to 260.3) | 179.6 (137.8 to 234.1) |
| Influenza A H1N1 Antibody: Day 181 | 127.6 (95.9 to 169.7) | 164.1 (119.9 to 224.7) | 167.8 (122.4 to 230.0) | 119.9 (82.4 to 174.5) | 123.8 (88.2 to 173.8) | 137.4 (106.1 to 177.9) |
| Influenza A H3N2 Antibody: Day 1 | 33.3 (26.3 to 42.3) | 46.4 (31.6 to 68.1) | 41.2 (32.8 to 51.9) | 37.2 (26.7 to 51.9) | 29.7 (21.5 to 40.9) | 27.4 (21.8 to 34.4) |
| Influenza A H3N2 Antibody: Day 8 | 125.6 (88.7 to 178.1) | 187.9 (128.2 to 275.5) | 188.4 (147.5 to 240.6) | 109.1 (71.4 to 166.6) | 125.0 (80.0 to 195.2) | 162.3 (118.2 to 222.8) |
| Influenza A H3N2 Antibody: Day 29 | 159.0 (115.8 to 218.4) | 262.7 (170.9 to 403.8) | 248.2 (192.2 to 320.6) | 124.4 (78.2 to 198.1) | 136.2 (89.7 to 206.9) | 160.0 (118.7 to 215.7) |
| Influenza A H3N2 Antibody: Day 91 | 105.1 (77.3 to 142.7) | 146.8 (101.4 to 212.6) | 154.8 (116.6 to 205.5) | 99.5 (69.8 to 141.9) | 94.0 (66.9 to 132.0) | 103.6 (80.0 to 134.0) |
| Influenza A H3N2 Antibody: Day 181 | 87.8 (66.0 to 116.8) | 124.9 (84.6 to 184.2) | 107.9 (81.7 to 142.3) | 68.2 (46.4 to 100.4) | 67.7 (48.3 to 94.8) | 87.0 (65.2 to 116.2) |
| Influenza B/ Victoria Lineage: Day 1 | 63.4 (55.1 to 72.9) | 78.1 (60.5 to 100.9) | 82.5 (66.9 to 101.8) | 74.5 (59.4 to 93.4) | 64.0 (49.8 to 82.3) | 67.8 (58.2 to 78.9) |
| Influenza B/ Victoria Lineage: Day 8 | 88.9 (72.2 to 109.3) | 164.0 (119.5 to 225.1) | 194.7 (145.8 to 260.0) | 150.7 (112.2 to 202.4) | 129.6 (91.9 to 182.8) | 126.4 (100.7 to 158.7) |
| Influenza B/ Victoria Lineage: Day 29 | 94.3 (75.4 to 117.8) | 174.5 (124.2 to 245.3) | 218.0 (160.3 to 296.5) | 132.2 (99.2 to 176.2) | 120.4 (90.3 to 160.6) | 132.8 (104.2 to 169.3) |
| Influenza B/ Victoria Lineage: Day 91 | 89.2 (77.2 to 103.2) | 126.5 (100.9 to 158.5) | 138.2 (109.6 to 174.2) | 100.9 (78.2 to 130.1) | 84.1 (66.4 to 106.5) | 94.2 (80.8 to 109.7) |
| Influenza B/ Victoria Lineage: Day 181 | 62.9 (53.7 to 73.7) | 75.2 (56.2 to 100.5) | 83.9 (68.5 to 102.7) | 59.9 (47.2 to 76.1) | 60.3 (49.7 to 73.2) | 60.2 (51.8 to 69.9) |
| Influenza B/ Yamagata Lineage: Day 1 | 71.9 (57.6 to 89.7) | 107.7 (72.3 to 160.4) | 96.3 (75.6 to 122.8) | 99.2 (70.0 to 140.5) | 77.1 (57.3 to 103.6) | 84.9 (67.4 to 106.9) |
| Influenza B/ Yamagata Lineage: Day 8 | 181.2 (142.0 to 231.1) | 293.5 (195.8 to 440.0) | 305.7 (233.2 to 400.8) | 198.3 (141.9 to 277.3) | 215.5 (155.2 to 299.2) | 367.6 (280.4 to 481.8) |
| Influenza B/ Yamagata Lineage: Day 29 | 181.5 (146.6 to 224.7) | 275.8 (187.5 to 405.8) | 336.2 (270.4 to 418.1) | 205.7 (142.4 to 297.0) | 187.9 (136.8 to 258.2) | 309.5 (246.8 to 388.1) |
| Influenza B/ Yamagata Lineage: Day 91 | 134.1 (112.7 to 159.5) | 190.3 (140.0 to 258.7) | 218.9 (173.4 to 276.2) | 160.0 (120.1 to 213.2) | 141.4 (107.8 to 185.5) | 194.8 (161.7 to 234.7) |
| Influenza B/ Yamagata Lineage: Day 181 | 109.4 (91.3 to 131.2) | 137.9 (101.0 to 188.3) | 140.6 (113.6 to 174.1) | 111.6 (79.5 to 156.4) | 125.4 (98.6 to 159.4) | 138.3 (114.3 to 167.4) |
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% confidence interval (CI) for GMFR was calculated based on the t distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
| ratio | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose |
|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody: Day 8 | 4.27 (3.13 to 5.783) | 4.47 (2.95 to 6.78) | 4.38 (3.18 to 6.04) | 3.07 (2.04 to 4.64) | 5.13 (3.40 to 7.75) | 6.87 (4.79 to 9.86) |
| Influenza A H1N1 Antibody: Day 29 | 6.38 (4.58 to 8.89) | 5.19 (3.37 to 7.99) | 5.42 (3.94 to 7.44) | 3.26 (2.15 to 4.95) | 5.32 (3.31 to 8.57) | 7.24 (5.16 to 10.17) |
| Influenza A H1N1 Antibody: Day 91 | 3.13 (2.36 to 4.17) | 3.32 (2.34 to 4.71) | 3.08 (2.24 to 4.25) | 2.05 (1.50 to 2.81) | 3.45 (1.94 to 6.13) | 3.71 (2.69 to 5.13) |
| Influenza A H1N1 Antibody: Day 181 | 2.36 (1.80 to 3.10) | 2.69 (1.88 to 3.86) | 2.23 (1.61 to 3.08) | 1.59 (1.14 to 2.21) | 2.43 (1.43 to 4.12) | 2.87 (2.12 to 3.88) |
| Influenza A H3N2 Antibody: Day 8 | 3.82 (2.87 to 5.08) | 4.05 (3.03 to 5.42) | 4.44 (3.46 to 5.71) | 2.93 (2.05 to 4.19) | 4.21 (2.82 to 6.29) | 6.11 (4.65 to 8.02) |
| Influenza A H3N2 Antibody: Day 29 | 4.77 (3.74 to 6.09) | 5.66 (3.98 to 8.06) | 6.02 (4.68 to 7.75) | 3.34 (2.27 to 4.91) | 4.59 (3.08 to 6.83) | 5.85 (4.49 to 7.61) |
| Influenza A H3N2 Antibody: Day 91 | 3.11 (2.47 to 3.93) | 3.17 (2.20 to 4.55) | 3.79 (2.81 to 5.12) | 2.76 (1.91 to 3.99) | 3.17 (2.14 to 4.69) | 3.76 (3.05 to 4.65) |
| Influenza A H3N2 Antibody: Day 181 | 2.59 (2.06 to 3.26) | 2.69 (2.01 to 3.61) | 2.66 (1.99 to 3.55) | 2.06 (1.43 to 2.97) | 2.25 (1.60 to 3.16) | 3.14 (2.47 to 4.00) |
| Influenza B/Victoria Lineage: Day 8 | 1.41 (1.20 to 1.65) | 2.10 (1.53 to 2.88) | 2.39 (1.93 to 3.00) | 2.02 (1.59 to 2.58) | 2.03 (1.62 to 2.52) | 1.90 (1.58 to 2.30) |
| Influenza B/Victoria Lineage: Day 29 | 1.49 (1.26 to 1.76) | 2.23 (1.65 to 3.03) | 2.64 (2.11 to 3.31) | 1.78 (1.40 to 2.26) | 1.88 (1.54 to 2.29) | 1.96 (1.61 to 2.38) |
| Influenza B/Victoria Lineage: Day 91 | 1.36 (1.16 to 1.59) | 1.62 (1.27 to 2.06) | 1.65 (1.38 to 1.97) | 1.34 (1.04 to 1.73) | 1.31 (1.04 to 1.66) | 1.39 (1.19 to 1.64) |
| Influenza B/Victoria Lineage: Day 181 | 0.95 (0.79 to 1.15) | 0.96 (0.75 to 1.24) | 0.98 (0.81 to 1.19) | 0.74 (0.55 to 0.99) | 0.93 (0.74 to 1.15) | 0.89 (0.73 to 1.09) |
| Influenza B/Yamagata Lineage: Day 8 | 2.53 (2.02 to 3.17) | 2.73 (2.04 to 3.65) | 3.20 (2.42 to 4.23) | 2.00 (1.49 to 2.68) | 2.80 (2.07 to 3.78) | 4.32 (3.41 to 5.47) |
| Influenza B/Yamagata Lineage: Day 29 | 2.53 (2.04 to 3.12) | 2.56 (1.99 to 3.29) | 3.49 (2.72 to 4.48) | 2.07 (1.75 to 2.74) | 2.44 (1.75 to 3.39) | 3.65 (2.90 to 4.59) |
| Influenza B/Yamagata Lineage: Day 91 | 1.83 (1.54 to 2.17) | 1.77 (1.42 to 2.20) | 2.21 (1.78 to 2.74) | 1.59 (1.24 to 2.03) | 1.83 (1.37 to 2.46) | 2.29 (1.88 to 2.80) |
| Influenza B/Yamagata Lineage: Day 181 | 1.47 (1.24 to 1.75) | 1.28 (0.97 to 1.69) | 1.41 (1.13 to 1.76) | 1.09 (0.84 to 1.42) | 1.61 (1.22 to 2.13) | 1.63 (1.34 to 1.97) |
Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroresponse was defined as (a) a post-vaccination antibody titer ≥ 4 \* lower limit of quantification (LLOQ) if baseline (Day 1) antibody titer was \< LLOQ or (b) a post-vaccination antibody titer ≥ 4-fold of baseline antibody titer if baseline antibody titer was ≥ LLOQ.
| percentage of participants | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose |
|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody: Day 8 | 54.7 (40.4 to 68.4) | 50.0 (30.6 to 69.4) | 50.9 (36.8 to 64.9) | 31.0 (15.3 to 50.8) | 60.7 (40.6 to 78.5) | 70.0 (55.4 to 82.1) |
| Influenza A H1N1 Antibody: Day 29 | 69.1 (55.2 to 80.9) | 53.6 (33.9 to 72.5) | 60.7 (46.8 to 73.5) | 41.4 (23.5 to 61.1) | 60.7 (40.6 to 78.5) | 69.2 (54.9 to 81.3) |
| Influenza A H1N1 Antibody: Day 91 | 58.8 (44.2 to 72.4) | 50.0 (30.6 to 69.4) | 38.5 (25.3 to 53.0) | 29.6 (13.8 to 50.2) | 42.9 (24.5 to 62.8) | 51.0 (36.6 to 65.2) |
| Influenza A H1N1 Antibody: Day 181 | 36.5 (23.6 to 51.0) | 39.3 (21.5 to 59.4) | 31.4 (19.1 to 45.9) | 16.7 (4.7 to 37.4) | 37.0 (19.4 to 57.6) | 42.0 (28.2 to 56.8) |
| Influenza A H3N2 Antibody: Day 8 | 54.7 (40.4 to 68.4) | 67.9 (47.6 to 84.1) | 56.6 (42.3 to 70.2) | 41.4 (23.5 to 61.1) | 57.1 (37.2 to 75.5) | 70.0 (55.4 to 82.1) |
| Influenza A H3N2 Antibody: Day 29 | 65.5 (51.4 to 77.8) | 67.9 (47.6 to 84.1) | 73.2 (59.7 to 84.2) | 58.6 (38.9 to 76.5) | 64.3 (44.1 to 81.4) | 69.2 (54.9 to 81.3) |
| Influenza A H3N2 Antibody: Day 91 | 54.9 (40.3 to 68.9) | 50.0 (30.6 to 69.4) | 57.7 (43.2 to 71.3) | 40.7 (22.4 to 61.2) | 60.7 (40.6 to 78.5) | 56.9 (42.2 to 70.7) |
| Influenza A H3N2 Antibody: Day 181 | 42.3 (28.7 to 56.8) | 35.7 (18.6 to 55.9) | 45.1 (31.1 to 59.7) | 25.0 (9.8 to 46.7) | 37.0 (19.4 to 57.6) | 48.0 (33.7 to 62.6) |
| Influenza B/Victoria Lineage: Day 8 | 11.3 (4.3 to 23.0) | 17.9 (6.1 to 36.9) | 28.3 (16.8 to 42.3) | 20.7 (8.0 to 39.7) | 17.9 (6.1 to 36.9) | 18.0 (8.6 to 31.4) |
| Influenza B/Victoria Lineage: Day 29 | 12.7 (5.3 to 24.5) | 25.0 (10.7 to 44.9) | 35.7 (23.4 to 49.6) | 17.2 (5.8 to 35.8) | 14.3 (4.0 to 32.7) | 19.2 (9.6 to 32.5) |
| Influenza B/Victoria Lineage: Day 91 | 3.9 (0.5 to 13.5) | 14.3 (4.0 to 32.7) | 17.3 (8.2 to 30.3) | 11.1 (2.4 to 29.2) | 3.6 (0.1 to 18.3) | 3.9 (0.5 to 13.5) |
| Influenza B/Victoria Lineage: Day 181 | 5.8 (1.2 to 15.9) | 7.1 (0.9 to 23.5) | 3.9 (0.5 to 13.5) | 4.2 (0.1 to 21.1) | 0 (0.0 to 12.8) | 4.0 (0.5 to 13.7) |
| Influenza B/Yamagata Lineage: Day 8 | 35.8 (23.1 to 50.2) | 39.3 (21.5 to 59.4) | 39.6 (26.5 to 54.0) | 20.7 (8.0 to 39.7) | 28.6 (13.2 to 48.7) | 62.0 (47.2 to 75.3) |
| Influenza B/Yamagata Lineage: Day 29 | 29.1 (17.6 to 42.9) | 32.1 (15.9 to 52.4) | 50.0 (36.3 to 63.7) | 27.6 (12.7 to 47.2) | 25.0 (10.7 to 44.9) | 53.8 (39.5 to 67.8) |
| Influenza B/Yamagata Lineage: Day 91 | 17.6 (8.4 to 30.9) | 14.3 (4.0 to 32.7) | 26.9 (15.6 to 41.0) | 14.8 (4.2 to 33.7) | 21.4 (8.3 to 41.0) | 31.4 (19.1 to 45.9) |
| Influenza B/Yamagata Lineage: Day 181 | 11.5 (4.4 to 23.4) | 10.7 (2.3 to 28.2) | 11.8 (4.4 to 23.9) | 4.2 (0.1 to 21.1) | 11.1 (2.4 to 29.2) | 16.0 (7.2 to 29.1) |
Collected over Day 1 up to the end of study (Day 181). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| mRNA-1010 | 0/60 (0%) | 1/60 (1.7%) | 0/60 (0%) |
| mRNA-1010.4 Low Dose | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| mRNA-1010.4 High Dose | 0/60 (0%) | 2/60 (3.3%) | 0/60 (0%) |
| mRNA-1010.6 Low Dose | 0/30 (0%) | 1/30 (3.3%) | 0/30 (0%) |
| mRNA-1010.6 Medium Dose | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| mRNA-1010.6 High Dose | 0/59 (0%) | 1/59 (1.7%) | 3/59 (5.1%) |
| Event | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose |
|---|---|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/60 | 0/30 | 0/60 | 1/30 | 0/31 | 0/59 |
| PancreatitisGastrointestinal disorders | 0/60 | 0/30 | 0/60 | 0/30 | 0/31 | 1/59 |
| CellulitisInfections and infestations | 0/60 | 0/30 | 1/60 | 0/30 | 0/31 | 0/59 |
| Hypertensive emergencyVascular disorders | 0/60 | 0/30 | 1/60 | 0/30 | 0/31 | 0/59 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/60 | 0/30 | 0/60 | 0/30 | 0/31 | 0/59 |
| Event | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose |
|---|---|---|---|---|---|---|
| EcchymosisSkin and subcutaneous tissue disorders | 0/60 | 0/30 | 0/60 | 0/30 | 0/31 | 3/59 |
Full Analysis Set included all randomized participants who received the study intervention.
| Age, Continuous(years) | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose | Total |
|---|---|---|---|---|---|---|---|
| Mean | 34.5 ± 9.08 | 36.7 ± 8.06 | 34.6 ± 7.87 | 36.7 ± 9.05 | 35.9 ± 7.56 | 33.8 ± 7.54 | 35.0 ± 8.20 |
| Sex: Female, Male(Participants) | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose | Total |
|---|---|---|---|---|---|---|---|
| Female | 34 | 17 | 40 | 13 | 17 | 31 | 152 |
| Male | 26 | 13 | 20 | 17 | 13 | 29 | 118 |
| Ethnicity (NIH/OMB)(Participants) | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 18 | 6 | 25 | 7 | 12 | 19 | 87 |
| Not Hispanic or Latino | 39 | 24 | 33 | 21 | 18 | 40 | 175 |
| Unknown or Not Reported | 3 | 0 | 2 | 2 | 0 | 1 | 8 |
| Race (NIH/OMB)(Participants) | mRNA-1010 | mRNA-1010.4 Low Dose | mRNA-1010.4 High Dose | mRNA-1010.6 Low Dose | mRNA-1010.6 Medium Dose | mRNA-1010.6 High Dose | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| Asian | 2 | 2 | 4 | 0 | 0 | 2 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 24 | 12 | 17 | 14 | 10 | 17 | 94 |
| White | 29 | 14 | 35 | 14 | 18 | 37 | 147 |
| More than one race | 4 | 1 | 1 | 0 | 1 | 1 | 8 |
| Unknown or Not Reported | 1 | 1 | 3 | 1 | 1 | 2 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2023 to primary completion in Dec 2023, 7 months.
Results were first posted in Dec 2024, 1 year after primary completion.
Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 7 months is close to that.
Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA-1010 influenza vaccine